Furthermore, a polyclonal antibody against the neonatal splice variant of NaV1.5 significantly reduces the invasive capacity of MDA-MB-231 breast cancer cells in a dose-dependent manner, underscoring its therapeutic potential in breast cancer [24]. This evidence concerns the gene SCN5A and breast cancer.